Found: 28
Select item for more details and to access through your institution.
Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Estimating a normal reference range for serum B‐cell maturation antigen levels for multiple myeloma patients.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 6, p. 1064, doi. 10.1111/bjh.16673
- By:
- Publication type:
- Article
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand‐1 (PD‐L1) expression and increases anti‐tumour effects of T cells in multiple myeloma.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 3, p. 568, doi. 10.1111/bjh.17282
- By:
- Publication type:
- Article
Normalization of serum B‐cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 2, p. 272, doi. 10.1111/bjh.16752
- By:
- Publication type:
- Article
JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.
- Published in:
- British Journal of Haematology, 2020, v. 188, n. 2, p. 283, doi. 10.1111/bjh.16158
- By:
- Publication type:
- Article
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 1, p. 60, doi. 10.1111/bjh.14992
- By:
- Publication type:
- Article
Reversal of dual epigenetic repression of non-canonical Wnt-5a normalises diabetic corneal epithelial wound healing and stem cells.
- Published in:
- Diabetologia, 2023, v. 66, n. 10, p. 1943, doi. 10.1007/s00125-023-05960-1
- By:
- Publication type:
- Article
The UBC9 E2 SUMO Conjugating Enzyme Binds the PR-Set7 Histone Methyltransferase to Facilitate Target Gene Repression.
- Published in:
- PLoS ONE, 2011, v. 6, n. 7, p. 1, doi. 10.1371/journal.pone.0022785
- By:
- Publication type:
- Article
Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients—a single-center retrospective study.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 8, p. 2061, doi. 10.1007/s00277-021-04555-3
- By:
- Publication type:
- Article
Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 4, p. 1079, doi. 10.1007/s00277-020-04351-5
- By:
- Publication type:
- Article
Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
- Published in:
- 2017
- By:
- Publication type:
- journal article
PR-Set7-mediated monomethylation of histone H4 lysine 20 at specific genomic regions induces transcriptional repression.
- Published in:
- Journal of Cellular Biochemistry, 2010, v. 110, n. 3, p. 609, doi. 10.1002/jcb.22570
- By:
- Publication type:
- Article
Baseline serum B‐cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
- Published in:
- European Journal of Haematology, 2021, v. 107, n. 3, p. 318, doi. 10.1111/ejh.13666
- By:
- Publication type:
- Article
The Role of JAK Inhibitors in Multiple Myeloma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2019, v. 17, n. 9, p. 500
- By:
- Publication type:
- Article
Ring around the genes.
- Published in:
- Nature Cell Biology, 2007, v. 9, n. 12, p. 1343, doi. 10.1038/ncb1207-1343
- By:
- Publication type:
- Article
Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study.
- Published in:
- European Journal of Haematology, 2018, v. 100, n. 6, p. 621, doi. 10.1111/ejh.13058
- By:
- Publication type:
- Article
Risk of skin cancer in multiple myeloma patients: a retrospective cohort study.
- Published in:
- European Journal of Haematology, 2016, v. 97, n. 5, p. 439, doi. 10.1111/ejh.12748
- By:
- Publication type:
- Article
Treatment With Elotuzumab in Combination With Dexamethasone Achieves a Complete Remission in a Previously Treated Patient With Multiple Myeloma: A Case Report.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy of Topical Use Crisaborole 2% Ointment for Treatment of Necrobiotic Xanthogranuloma Associated With Multiple Myeloma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Removal of a Silicone Gel Breast Implant in a Multiple Myeloma Patient Improved Disease Status: A Case Report.
- Published in:
- Case Reports in Oncology, 2020, v. 13, n. 3, p. 1103, doi. 10.1159/000508494
- By:
- Publication type:
- Article
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 906, doi. 10.1002/hon.3066
- By:
- Publication type:
- Article
Use of serum B‐cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 243, doi. 10.1002/hon.2961
- By:
- Publication type:
- Article
Monitoring Multiple Myeloma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2017, v. 15, n. 12, p. 951
- By:
- Publication type:
- Article
Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 4, p. 503, doi. 10.1007/s11523-021-00821-6
- By:
- Publication type:
- Article
Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia.
- Published in:
- 2019
- By:
- Publication type:
- journal article